Qilu Pharma Reports Data on Phase 2 Trial of Iparomlimab in Treating Progressive Solid Cancers, Reveals 45.8% Objective Response Rate at ESMO Asia Conference.

First patient with swiftly advancing ANCA-Related Vasculitis and kidney inflammation enrolled and treated in Phase II study of new drug Lixudebart (ALE.F02) by Alentis Therapeutics.

GT Biopharma, Inc., a clinical-stage immuno-oncology company, is committed to developing innovative therapies using its proprietary TriKE® NK cell technology. The firm recently announced it filed an IND application with the US FDA for its new drug, GTB-3650.

Everest Medicines, a biopharma company, announced that China's National Medical Products Administration has accepted their IND application for the drug candidate zetomipzomib in China.

FDA Grants Approval for CARsgen's Experimental Treatment CT071 for Use in Cases of Recurrent Multiple Myeloma and Primary Plasma Cell Leukemia After Prior Therapies Fail.

Brenig Therapeutics Reveals Enhanced Safety Metrics for its LRRK2 Blocker BT-0267 Featuring Notable CSF-to-Blood Concentration at the Parkinson's Disease Symposium.

The prominent science and technology corporation, Merck, has declared a formal licensing contract with the Shanghai-based firm Abbisko Therapeutics Co. Ltd.

Ascletis Pharma Inc. has declared the commencement of a pivotal Phase III clinical study for its fatty acid synthase inhibitor, ASC40 (Denifanstat) , aimed at addressing the therapeutic needs of individuals with moderate to severe acne vulgaris.

Merus N.V. has revealed fresh interim clinical findings on their candidate molecule MCLA-129.

UCB has received the green light from European regulators to market ZILBRYSQ[®] (zilucoplan) as a therapeutic option for generalized Myasthenia Gravis in adult patients.

Sana Biotechnology Releases Initial Clinical Findings Demonstrating SC291, an Off-the-Shelf CAR T Treatment Targeting CD19, Remains Undetected by a Functional Immune System.

Benitec Biopharma has reported initial dosing in an early-stage trial for its genetic treatment prospect, BB-301, aimed at tackling Oculopharyngeal Muscular Dystrophy.